Compare DexCom, Inc. (DXCM) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs UnitedHealth Group Inc — how do they compare? DexCom, Inc. trades at $77.71 (market cap $28.06B), while UnitedHealth Group Inc trades at $422.99 (market cap $380.08B). The key difference: UnitedHealth Group Inc is far larger — about 13.5× DexCom, Inc.'s market cap, and UnitedHealth Group Inc pays a 2.22% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | UNH | |
|---|---|---|
Market Cap | $28.06B | $380.08B |
Sector | Health | Health |
52-Week High | $89.53 | $431.68 |
52-Week Low | $54.84 | $237.77 |
Enterprise Value | $27.03B | $426.76B |
Dividend Yield | — | 2.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
UnitedHealth Group (UNH) trades at $425.19, down 0.91% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with revenue growth to $447.57B in 2025 and consistent earnings beats, though net margins have compressed. Recent news highlights strategic moves to reduce pediatric prior authorizations, aiming to improve care access and operational efficiency.
Outlook remains positive with an 82.69% analyst buy rating and $438.33 consensus target, but risks include regulatory lawsuits and debt levels. The aging U.S. population and tech investments provide growth tailwinds, yet investors should monitor margin pressures and legal challenges from state Medicaid suits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
